P/E at 29.89 vs Industry's 36.96: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount to Industry P/E

The current P/E of 29.89 for Dr Reddys Laboratories Ltd represents a discount of approximately 19% relative to the sector average of 36.96. This valuation gap suggests the market is pricing in either subdued growth expectations or elevated risks compared to peers. Given the pharmaceutical sector’s typical premium valuations driven by innovation and patent portfolios, this discount merits close attention. It raises the question of whether the stock’s lower P/E reflects a value opportunity or a justified caution — previously rated Hold, what is Dr Reddys Laboratories Ltd’s current rating?

Performance Across Timeframes: Divergent Momentum

Examining returns over multiple periods reveals a nuanced performance profile. Over the past year, Dr Reddys Laboratories Ltd has declined by 9.27%, underperforming the Sensex’s 5.35% loss. The one-month return of -1.79% is slightly better than the Sensex’s -2.69%, indicating some short-term resilience. However, the three-month return of -9.92% contrasts sharply with the Sensex’s 2.89% gain, signalling a recent acceleration in underperformance. Year-to-date, the stock’s -9.44% return is marginally better than the Sensex’s -10.36%, but the longer-term three- and five-year returns of 2.51% and 17.47% respectively lag the Sensex’s 15.28% and 31.08% by a wide margin. This divergence between short-term and medium-term returns — is this a temporary setback or a sign of deeper challenges? — complicates the investment narrative.

Moving Average Configuration: Bearish Technical Setup

The technical indicators for Dr Reddys Laboratories Ltd reveal a bearish trend. The stock is trading below all major moving averages: 5-day, 20-day, 50-day, 100-day, and 200-day. This alignment typically signals sustained downward momentum and a lack of short-term recovery. The absence of any bounce above short-term averages suggests that recent price action has failed to reverse the prevailing downtrend. The stock’s four consecutive days of losses, amounting to a cumulative decline of 1.79%, further reinforce this negative technical picture. The 1-day decline of 0.26% also slightly underperforms the sector’s 0.16% fall, indicating no immediate relief in sight.

Sector Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen mixed results in recent earnings announcements. Out of 34 stocks reporting, 14 delivered positive results, 15 remained flat, and 5 posted negative outcomes. This distribution suggests a broadly cautious environment with no clear sector-wide momentum. Dr Reddys Laboratories Ltd’s underperformance relative to the sector’s mixed earnings backdrop raises questions about its competitive positioning and operational execution. The stock’s mid-cap market capitalisation of ₹96,071.66 crores places it in a segment where growth and stability are both expected, yet the current data points to challenges in meeting these expectations — should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Rating Reassessment: From Hold to a New Evaluation

On 13 Jul 2026, the rating for Dr Reddys Laboratories Ltd was updated from a previous Hold rating. While the current rating is not disclosed, the reassessment reflects the evolving view of the company’s fundamentals and market conditions. The Mojo Score of 30.0, combined with the valuation discount and recent performance trends, suggests a cautious stance. The interplay between valuation, technical indicators, and sector performance forms the basis for this updated assessment — what is the current rating for Dr Reddys Laboratories Ltd?

Conclusion: A Complex Data-Driven Portrait

The data for Dr Reddys Laboratories Ltd reveals a stock trading at a valuation discount to its sector, yet facing persistent underperformance across multiple timeframes. The technical setup remains bearish with the stock below all key moving averages and a recent losing streak. Sector results are mixed, offering no clear tailwind, while the rating update from Hold signals a reassessment of the company’s outlook. Collectively, these factors suggest a cautious environment for the stock, raising important questions about its near-term trajectory and valuation justification — should investors reconsider their position in Dr Reddys Laboratories Ltd?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →